MedTrace Logo

PENG vs Deep Iliacus Plane Block in Intertrochanteric Femur Fractures

NCT07513740 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-04-07

No results posted yet for this study

Summary

Intertrochanteric femur fractures are common in elderly patients and are associated with significant pain. Providing effective analgesia is clinically important both during positioning for spinal anesthesia and in the postoperative period in this patient population.

The Pericapsular Nerve Group (PENG) block is a regional anesthesia technique that targets the articular branches of the hip capsule and may provide effective analgesia with motor-sparing potential. The Deep Iliacus Plane Block (DIPB) is a newer approach that may spread to both the articular branches and the lateral femoral cutaneous nerve.

Although both blocks are used in patients with intertrochanteric fractures, there is a lack of sufficient randomized controlled data comparing their effectiveness for pain during positioning for spinal anesthesia and for postoperative analgesia. Therefore, it is important to determine which technique provides greater clinical benefit.

The aim of this study is to compare the analgesic efficacy of the PENG block and the Deep Iliacus Plane Block during positioning for spinal anesthesia and in the postoperative period in patients undergoing surgery for intertrochanteric femur fractures.

Conditions

  • Postoperative Analgesia
  • Hip Surgery

Interventions

DRUG

Intravenous Analgesia

Standard preoperative intravenous analgesia according to institutional protocol.

PROCEDURE

Pericapsular nerve group (PENG) block

Ultrasound-guided PENG block with injection of 30 mL of 0.25% bupivacaine.

PROCEDURE

Deep Iliacus Plane Block (DIPB)

Ultrasound-guided Deep Iliacus Plane Block with injection of 30 mL of 0.25% bupivacaine.

Sponsors & Collaborators

  • Erzincan Binali Yildirim Universitesi

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2027-03-01
Completion
2027-03-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07513740 on ClinicalTrials.gov